Lead by proven industry experience, Marvel is at the forefront of modern science.

We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the traditional long-term biotech model.

The Company has been specifically focused on the discovery of new chemical entities that inhibits the A2a adenosine receptor. The A2a receptor is a target for a number of diseases representing areas of significant unmet medical needs, each with multi-billion dollar potential, and with fundamentally no competitors.

Our drug assets are targeted for the treatment of large and growing markets associated with a predominantly aging population.

 

The Company is targeting specifically

Neurological Diseases
that have not been treated with
conventional therapeutics

Non-Alcoholic
Steatohepatitis (NASH)
Currently no approved therapies

Cancer
Pursuing as an adjunctive
therapy

Stock Information

 

Shares Outstanding : 32,586,231
Insider Ownership : 12,525,098 (38.4%)
Warrant coverage : 10,071,533
Stock options granted : 2,825,000

Corporate Presentation

Download here

 

Recent News

Contact

Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2

Marvel Biosciences

Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.

Email Us

12 + 7 =